v3.26.1
Equity-Accounted Investees and Joint Business - Albajuna Therapeutics, S.L. (Details) - EUR (€)
€ in Thousands
12 Months Ended
Mar. 07, 2025
Oct. 09, 2023
Dec. 31, 2018
Dec. 31, 2016
Grifols Innovation and New Technologies Limited        
Equity-Accounted Investees and Joint Business        
Proportion of ownership interest (as a percent) 100.00% 100.00%    
Albajuna Therapeutics, S.L        
Equity-Accounted Investees and Joint Business        
Proportion of ownership interest (as a percent)   100.00%    
Albajuna Therapeutics, S.L        
Equity-Accounted Investees and Joint Business        
Percentage of interest acquired   51.00%    
Total business combination cost   € 1,000    
Albajuna Therapeutics, S.L.        
Equity-Accounted Investees and Joint Business        
Capital investment       € 4,000
Percentage of shareholding     49.00% 30.00%